Investor Engagement

MediciNova’s management will engage stakeholders at the H.C. Wainwright 28th Annual Global Investment Conference and the ROTH Capital 5th Annual Healthcare Opportunities Conference this month, offering updates on clinical progress and demonstrating a commitment to investor dialogue. The company plans to announce topline results from its Phase 2 MN‑001‑NATG‑202 study in metabolic disease by the end of Q3 and from the double‑blind phase of its lead program, COMBAT‑ALS, by year‑end. As of Q2 2026, MediciNova maintains a $25.4 million cash balance, positioning it to sustain development activities and deliver optimal shareholder value. Late‑stage pipeline programs include MN‑166 (ibudilast) and MN‑001 (tipelukast), both featuring strong safety profiles and diverse mechanisms of action. The firm’s history of securing investigator‑sponsored trials funded through government grants adds to its development cost base. Virtual presentations from the conferences will allow investors to access detailed insights, reinforcing transparency and potentially influencing capital‑market perception.